Literature DB >> 32307511

Strongyloides stercoralis Coinfection Is Associated With Greater Disease Severity, Higher Bacterial Burden, and Elevated Plasma Matrix Metalloproteinases in Pulmonary Tuberculosis.

Nathella P Kumar1, Gokul R Kathamuthu1, Kadar Moideen1, Vaithilingam V Banurekha2, Dina Nair2, Michael P Fay3, Thomas B Nutman4, Subash Babu1,4.   

Abstract

BACKGROUND: Helminths and tuberculosis (TB) largely overlap at the population level. Whether helminth infections influence disease severity and bacterial burdens in TB is not well understood.
METHODS: This study was conducted to examine the disease severity in a cohort of pulmonary TB (PTB) individuals with (Ss+) or without (Ss-) seropositivity for Strongyloides stercoralis infection.
RESULTS: Ss+ was associated with increased risk of cavitation (odds ratio [OR], 4.54; 95% confidence interval [CI], 2.33-9.04; P < .0001) and bilateral lung involvement (OR, 5.97; 95% CI, 3.03-12.09; P < .0001) in PTB individuals. Ss+ was also associated with higher bacterial burdens (OR, 7.57; 95% CI, 4.18-14.05; P < .0001) in PTB individuals. After multivariate analysis adjusting for covariates, Ss+ was still associated with greater risk of cavitation (adjusted OR [aOR], 3.99; 95% CI, 1.73-9.19; P = .0014), bilateral lung involvement (aOR, 4.09; 95% CI, 1.78-9.41; P = .0011), and higher bacterial burden (aOR, 9.32; 95% CI, 6.30-13.96; P < .0001). Finally, Ss+ was also associated with higher plasma levels of matrix metalloproteinases ([MMP]-1, -2, -7, -8, and -9) in PTB individuals.
CONCLUSIONS: Therefore, our data demonstrate that coexistent Ss infection is associated with greater disease severity and higher bacterial burden in PTB. Our data also demonstrate enhanced plasma levels of MMPs in coinfected individuals, suggesting a plausible biological mechanism for these effects. Published by Oxford University Press for the Infectious Diseases Society of America 2020.

Entities:  

Keywords:  MMPs; disease severity; helminths; tuberculosis

Year:  2020        PMID: 32307511      PMCID: PMC7430190          DOI: 10.1093/infdis/jiaa194

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  29 in total

1.  Intestinal helminth co-infection has a negative impact on both anti-Mycobacterium tuberculosis immunity and clinical response to tuberculosis therapy.

Authors:  T Resende Co; C S Hirsch; Z Toossi; R Dietze; R Ribeiro-Rodrigues
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

Review 2.  Control of neglected tropical diseases.

Authors:  Peter J Hotez; David H Molyneux; Alan Fenwick; Jacob Kumaresan; Sonia Ehrlich Sachs; Jeffrey D Sachs; Lorenzo Savioli
Journal:  N Engl J Med       Date:  2007-09-06       Impact factor: 91.245

3.  Microbial Translocation Associated with an Acute-Phase Response and Elevations in MMP-1, HO-1, and Proinflammatory Cytokines in Strongyloides stercoralis Infection.

Authors:  Anuradha Rajamanickam; Saravanan Munisankar; Yukthi Bhootra; Chandrakumar Dolla; Thomas B Nutman; Subash Babu
Journal:  Infect Immun       Date:  2016-12-29       Impact factor: 3.441

4.  Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients.

Authors:  A C Hesseling; G Walzl; D A Enarson; N M Carroll; K Duncan; P T Lukey; C Lombard; P R Donald; K A Lawrence; R P Gie; P D van Helden; N Beyers
Journal:  Int J Tuberc Lung Dis       Date:  2010-05       Impact factor: 2.373

5.  Expression of metalloproteinases (MMP-1, MMP-2, and MMP-9) and their inhibitors (TIMP-1 and TIMP-2) in schistosomal portal fibrosis.

Authors:  D E Gomez; M S De Lorenzo; D F Alonso; Z A Andrade
Journal:  Am J Trop Med Hyg       Date:  1999-07       Impact factor: 2.345

6.  Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.

Authors:  Debra Benator; Mondira Bhattacharya; Lorna Bozeman; William Burman; Antonino Cantazaro; Richard Chaisson; Fred Gordin; C Robert Horsburgh; James Horton; Awal Khan; Christopher Lahart; Beverly Metchock; Constance Pachucki; Llewellyn Stanton; Andrew Vernon; M Elsa Villarino; Yong Chen Wang; Marc Weiner; Stephen Weis
Journal:  Lancet       Date:  2002-08-17       Impact factor: 79.321

Review 7.  The Immune Mechanisms of Lung Parenchymal Damage in Tuberculosis and the Role of Host-Directed Therapy.

Authors:  Cari Stek; Brian Allwood; Naomi F Walker; Robert J Wilkinson; Lutgarde Lynen; Graeme Meintjes
Journal:  Front Microbiol       Date:  2018-10-30       Impact factor: 5.640

8.  Asymptomatic Helminth Infection in Active Tuberculosis Is Associated with Increased Regulatory and Th-2 Responses and a Lower Sputum Smear Positivity.

Authors:  Ebba Abate; Meseret Belayneh; Jonna Idh; Ermias Diro; Daniel Elias; Sven Britton; Abraham Aseffa; Olle Stendahl; Thomas Schön
Journal:  PLoS Negl Trop Dis       Date:  2015-08-06

9.  Incidence of active pulmonary tuberculosis in patients with coincident filarial and/or intestinal helminth infections followed longitudinally in South India.

Authors:  Soumya Chatterjee; Chockalingam Kolappan; Rangasamy Subramani; Punnathanathu G Gopi; Vedhachalam Chandrasekaran; Michael P Fay; Subash Babu; Vasanthapuram Kumaraswami; Thomas B Nutman
Journal:  PLoS One       Date:  2014-04-11       Impact factor: 3.240

10.  Diagnostic accuracy of five serologic tests for Strongyloides stercoralis infection.

Authors:  Zeno Bisoffi; Dora Buonfrate; Marco Sequi; Rojelio Mejia; Ruben O Cimino; Alejandro J Krolewiecki; Marco Albonico; Maria Gobbo; Stefania Bonafini; Andrea Angheben; Ana Requena-Mendez; José Muñoz; Thomas B Nutman
Journal:  PLoS Negl Trop Dis       Date:  2014-01-09
View more
  2 in total

Review 1.  Soil-Transmitted Helminth Vaccines: Are We Getting Closer?

Authors:  Ayat Zawawi; Kathryn J Else
Journal:  Front Immunol       Date:  2020-09-30       Impact factor: 7.561

2.  Helminth species dependent effects on Th1 and Th17 cytokines in active tuberculosis patients and healthy community controls.

Authors:  Gezahegn Bewket; Amare Kiflie; Fitsumbrhan Tajebe; Ebba Abate; Thomas Schön; Robert Blomgran
Journal:  PLoS Negl Trop Dis       Date:  2022-08-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.